WHO grade Ⅱ-Ⅲ神経膠腫の遺伝子異常とその生物学的意義
2016 年 23 巻 2 号 p. 13-21
詳細
2016 年 23 巻 2 号 p. 13-21
Gliomas have been diagnosed according to the histological classification published by the World Health Organization (WHO). However, recent advance in tumor genetics validated clinical value of genetic analysis in glioma management, and genetic classification is considered to have advantage to histological classification in predicting the patients’ outcome. In 2016, WHO revised classification of tumors of the central nervous system, and remarkable revision was made in various tumors. Of them, classification of diffuse glioma of lower grade was advanced in practical manner. Those tumors are classified by key genetic aberrations including mutation of isocitrate dehydrogenase 1/2 gene (IDH1/2) and codeletion of chromosomal arms 1p and 19q. Mutation in TP53, ATRX and promoter of TERT are helpful in subgrouping the tumors.
In this review, biological aspects of genetic aberrations applied to 2016 WHO classification are discussed to help understanding of oncology in relation with management for grade II-III diffuse gliomas.
